摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Methoxy-3,6-dimethylpyridine | 1121585-23-6

中文名称
——
中文别名
——
英文名称
2-Methoxy-3,6-dimethylpyridine
英文别名
——
2-Methoxy-3,6-dimethylpyridine化学式
CAS
1121585-23-6
化学式
C8H11NO
mdl
——
分子量
137.18
InChiKey
PROSRRABZRFGQL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    22.1
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • [EN] PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS.<br/>[FR] DÉRIVÉS DE PYRIMIDINE, PYRIDINE ET TRIAZINE EN TANT QU'OUVREURS DE CANAUX MAXI-K
    申请人:MITSUBISHI TANABE PHARMA CORP
    公开号:WO2009125870A1
    公开(公告)日:2009-10-15
    A compound of formula (A); wherein ring A is an aromatic ring or a heteroaromatic ring; R1 is independently halogen, cyano, etc., each of X1, X2 and X3 is CR2 or nitrogen, R2 is independently hydrogen, etc., n is 0, 1, 2, 3 or 4; -D-Y is -O-CH2COOH, etc, and G is a substituted amino, a substituted heterocyclic group, etc, or a pharmaceutical acceptable salt thereof, has activities of opening BK channels.
    化合物的结构式(A);其中环A是芳香环或杂芳环;R1独立地是卤素、氰基等;X1、X2和X3中的每一个是CR2或氮,R2独立地是氢等;n为0、1、2、3或4;-D-Y是-O-CH2COOH等;G是取代氨基、取代杂环基等,或其药用可接受盐,具有开放BK通道的活性。
  • [EN] NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES
    申请人:SANOFI SA
    公开号:WO2013150036A1
    公开(公告)日:2013-10-10
    The present invention relates to compounds of formula (I): wherein R6 is -CONH2 or a -C(Rα)(Rβ)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    本发明涉及式(I)化合物的制备过程及其治疗用途:其中R6是-CONH2或一个-C(Rα)(Rβ)(OH)基团;R是一个取代的苯基或杂芳基团;R7是一个可选地取代的芳基或杂芳基团。
  • NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF
    申请人:CARRY Jean-Christophe
    公开号:US20130261106A1
    公开(公告)日:2013-10-03
    The present invention relates to compounds of formula (I): wherein R6 is —CONH 2 or a —C(R α )(R β )(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    本发明涉及具有公式(I)的化合物: 其中R6是—CONH2或—C(Rα)(Rβ)(OH)基团;R是取代的苯基或杂芳基团;R7是可选地取代的芳基或杂芳基团。 其制备过程及其治疗用途。
  • 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE
    申请人:Horiuchi Yoshihiro
    公开号:US20120225876A1
    公开(公告)日:2012-09-06
    Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R 1a and R 1b may be the same or different and each independently represents a C 1-6 alkyl group which may be substituted by one to three halogen atoms; m and n each independently represents an integer of 0-5; X 1 represents a hydroxyl group or an aminocarbonyl group; Z 1 represents a single bond or the like; and R 2 represents an optionally substituted C 1-6 alkyl group, an optionally substituted C 6-10 aryl group or the like.)
    公开了一种由公式(1)表示的化合物或其药理可接受的盐(在公式中,A代表由公式(A-1)表示的基团;R1a和R1b可以相同或不同,每个独立地表示一个可以由一个到三个卤素原子取代的C1-6烷基;m和n各自独立地表示0-5之间的整数;X1代表羟基或氨基甲酰基;Z1代表单键等;R2代表一个可选地取代的C1-6烷基,一个可选地取代的C6-10芳基等)。
  • [EN] OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS D'OXADIAZINE ET LEURS PROCÉDÉS D'UTILISATION
    申请人:FORUM PHARMACEUTICALS INC
    公开号:WO2017031325A1
    公开(公告)日:2017-02-23
    The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.
    本公开涉及噁唑啉化合物,包括有效量的噁唑啉化合物的药物组合物,以及使用噁唑啉化合物治疗神经退行性疾病的方法,包括向需要的受试者施用有效量的噁唑啉化合物。
查看更多